(2-甲基苯并咪唑-1-基)乙酸 | 40332-17-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2-甲基苯并咪唑-1-基)乙酸
• 中文别名: (2-甲基苯并咪唑-1-)乙酸；(2-甲基-1H-苯并咪唑-1-基)乙酸
• 英文名称: 1-carboxymethyl-2-methylbenzimidazole
• 英文别名: 2-(2-methyl-1H-benzo[d]imidazol-1-yl)acetic acid；2-Methylbenzimidazol-N-essigsaeure；(2-methyl-benzoimidazol-1-yl)-acetic acid；(2-methyl-benzimidazol-1-yl)-acetic acid；(2-Methyl-benzimidazol-1-yl)-essigsaeure；(2-methyl-1H-benzimidazol-1-yl)acetic acid；2-(2-methylbenzimidazol-1-yl)acetic acid
• CAS: 40332-17-0
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD00621731
• 分子量: 190.202
• InChiKey: SMGBDFGKVGSCGB-UHFFFAOYSA-N

物化性质

• 熔点：
  260 °C
• 沸点：
  431.7±28.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (2-Methyl-1h-benzimidazol-1-yl)acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (2-Methyl-1h-benzimidazol-1-yl)acetic acid
CAS number: 40332-17-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10N2O2
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-甲基苯并咪唑-1-基)乙酸 在 对甲苯磺酸 作用下， 反应 7.0h， 生成 2-methyl-N-[(5-(2,4-dichlorophenylmethylene)amino-1,3,4-thiadiazol-2-yl)methyl]benzimidazole
  参考文献：
  名称：

  一种苯并咪唑类化合物及其制备方法和应用

  摘要：

  一种2‑取代‑N‑[5‑(2‑氨基‑1,3,4‑噻二唑)‑亚甲基]‑苯并咪唑及其制备方法和应用，首先以苯并咪唑类化合物和氯乙酸钾为原料，乙醇为溶剂回流反应制得1‑羧甲基‑苯并咪唑类化合物；然后以多聚磷酸、1‑羧甲基‑苯并咪唑类化合物以及氨基硫脲为原料，回流反应制得2‑取代‑N‑[5‑(2‑氨基‑1,3,4‑噻二唑)‑亚甲基]‑苯并咪唑；接着以2‑取代‑N‑[5‑(2‑氨基‑1,3,4‑噻二唑)‑亚甲基]‑苯并咪唑、芳醛以及对甲苯磺酸为原料进行固相反应，制得2‑取代‑N‑[5‑(2‑氨基‑1,3,4‑噻二唑)‑亚甲基]‑苯并咪唑。本发明反应过程简单，设备要求低，操作简单，目标产物产率较高，对环境污染小，制得的2‑取代‑N‑[5‑(2‑(N‑芳基亚甲基)氨基‑1,3,4‑噻二唑)‑亚甲基]‑苯并咪唑能够在制备抑制大肠杆菌的药物中应用。

  公开号：

  CN104130249B
• 作为产物：
  描述：

  benzyl 2-(2-methyl-1H-benzo[d]imidazol-1-yl)acetate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (2-甲基苯并咪唑-1-基)乙酸
  参考文献：
  名称：

  Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

  摘要：

  Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity based probe, could be used to pull down active endogenous KLK6.

  DOI：

  10.1021/acs.jmedchem.8b01106

文献信息

• Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria
  作者：Robert J. Moreau、Colin K. Skepper、Brent A. Appleton、Anke Blechschmidt、Carl J. Balibar、Bret M. Benton、Joseph E. Drumm、Brian Y. Feng、Mei Geng、Cindy Li、Mika K. Lindvall、Andreas Lingel、Yipin Lu、Mulugeta Mamo、Wosenu Mergo、Valery Polyakov、Thomas M. Smith、Kenneth Takeoka、Kyoko Uehara、Lisha Wang、Jun-Rong Wei、Andrew H. Weiss、Lili Xie、Wenjian Xu、Qiong Zhang、Javier de Vicente

  DOI：10.1021/acs.jmedchem.7b01691

  日期：2018.4.26

  The discovery and development of new antibiotics capable of curing infections due to multidrug-resistant and pandrug-resistant Gram-negative bacteria are a major challenge with fundamental importance to our global healthcare system. Part of our broad program at Novartis to address this urgent, unmet need includes the search for new agents that inhibit novel bacterial targets. Here we report the discovery

  能够治愈由多重耐药和泛耐药革兰氏阴性细菌引起的感染的新型抗生素的发现和开发是一项重大挑战，对我们的全球医疗体系至关重要。为解决这一紧迫而未满足的需求，我们在诺华广泛计划的一部分包括寻找抑制新细菌靶标的新药物。在这里，我们报道了革兰氏阴性细菌磷酸泛肽腺苷酸基转移酶（PPAT）的新型抑制剂的发现和领先优势的优化方法。利用基于片段的筛选方法，我们发现了许多能够与大肠杆菌PPAT的泛肽位点相互作用并抑制酶促活性的独特支架，包括三唑并吡咯烷二酮6。基于结构的优化可鉴定出两种先导化合物，它们是细菌PPAT的选择性小分子抑制剂：三唑并吡咯烷二酮53和氮杂苯并咪唑54可有效抑制大肠杆菌和铜绿假单胞菌PPAT，并显示出适度的细胞外排能力，可抵抗排泄不足的大肠杆菌。 Δ TOLC突变株。
• [EN] COMPOSITIONS FOR TRANSFECTING A NUCLEIC ACID MOLECULE INTO A CELL COMPRISING HETEROCYCLIC COMPOUNDS GRAFTED TO A CATIONIC POLYMER, AND THEIR APPLICATIONS<br/>[FR] COMPOSITIONS POUR LA TRANSFECTION D'UNE MOLÉCULE D'ACIDE NUCLÉIQUE DANS UNE CELLULE COMPRENANT DES COMPOSÉS HÉTÉROCYCLIQUES GREFFÉS À UN POLYMÈRE CATIONIQUE ET LEURS APPLICATIONS
  申请人：POLYPLUS TRANSFECTION

  公开号：WO2021023796A1

  公开（公告）日：2021-02-11

  The present invention relates to compositions for transfecting a nucleic acid molecule into a cell and their applications. The present invention is directed to a composition suitable for transfecting a nucleic acid molecule into a cell, preferably a eukaryotic cell, comprising (i) at least one compound of general formula (II) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or an acceptable salt thereof, and (ii) an acceptable excipient, buffering agent, cell culture medium, or transfection medium, wherein Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5, Z6, Z7, X1, X2, R3, P+, R, T, U and V are as defined in the description. The present invention also relates to uses of said composition and to a method for in vitro or ex vivo transfection of live cells.

  本发明涉及用于将核酸分子转染入细胞的组合物及其应用。本发明涉及一种适用于将核酸分子转染入细胞，特别是真核细胞的组合物，包括（i）至少一种一般式（II）的化合物或其互变异构体、互变异构体、外消旋体、对映体、非对映体或其混合物，或其可接受的盐，以及（ii）可接受的赋形剂、缓冲剂、细胞培养基或转染培养基，其中Y1、Y2、Y3、Z1、Z2、Z3、Z4、Z5、Z6、Z7、X1、X2、R3、P+、R、T、U和V的定义如描述中所述。本发明还涉及所述组合物的用途以及一种用于体外或体内细胞转染的方法。
• Transcription Factor Modulating Compounds and Methods of Use Thereof
  申请人：Alekshun Michael N.

  公开号：US20090131481A1

  公开（公告）日：2009-05-21

  Substituted benzimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of using substituted benzimidazole compounds, in, e.g., reducing virulence and infectivity, inhibiting biofilms and treating bacterial infections are also provided.

  提供了一种有用的取代苯并咪唑化合物，可用作抗感染剂，降低微生物的抗药性、毒力或生长。还提供了使用取代苯并咪唑化合物的方法，例如减少病原体的毒力和感染性、抑制生物膜和治疗细菌感染。
• IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS
  申请人：Eastwood Paul Robert

  公开号：US20130216498A1

  公开（公告）日：2013-08-22

  New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  本发明揭示了具有化学式（I）的新咪唑吡啶衍生物，以及它们的制备方法，包括它们的药物组合物和它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
  申请人：Samuel Rachel G.

  公开号：US20100286191A1

  公开（公告）日：2010-11-11

  The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

  本发明涵盖公式I的化合物或其药学上可接受的盐，它们是CXCR3趋化因子受体功能调节剂，可用于治疗或预防病原体炎症过程、自身免疫性疾病或移植排斥过程。本发明还涵盖使用方法和制药组合物。